Cargando…

Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis

INTRODUCTION: The first steps in goal-directed therapy for sepsis are early diagnosis followed by appropriate triage. These steps are usually left to the physician’s judgment, as there is no accepted biomarker available. We aimed to determine biomarker phenotypes that differentiate children with sep...

Descripción completa

Detalles Bibliográficos
Autores principales: Mickiewicz, Beata, Thompson, Graham C., Blackwood, Jaime, Jenne, Craig N., Winston, Brent W., Vogel, Hans J., Joffe, Ari R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563828/
https://www.ncbi.nlm.nih.gov/pubmed/26349677
http://dx.doi.org/10.1186/s13054-015-1026-2
_version_ 1782389338296811520
author Mickiewicz, Beata
Thompson, Graham C.
Blackwood, Jaime
Jenne, Craig N.
Winston, Brent W.
Vogel, Hans J.
Joffe, Ari R.
author_facet Mickiewicz, Beata
Thompson, Graham C.
Blackwood, Jaime
Jenne, Craig N.
Winston, Brent W.
Vogel, Hans J.
Joffe, Ari R.
author_sort Mickiewicz, Beata
collection PubMed
description INTRODUCTION: The first steps in goal-directed therapy for sepsis are early diagnosis followed by appropriate triage. These steps are usually left to the physician’s judgment, as there is no accepted biomarker available. We aimed to determine biomarker phenotypes that differentiate children with sepsis who require intensive care from those who do not. METHODS: We conducted a prospective, observational nested cohort study at two pediatric intensive care units (PICUs) and one pediatric emergency department (ED). Children ages 2–17 years presenting to the PICU or ED with sepsis or presenting for procedural sedation to the ED were enrolled. We used the judgment of regional pediatric ED and PICU attending physicians as the standard to determine triage location (PICU or ED). We performed metabolic and inflammatory protein mediator profiling with serum and plasma samples, respectively, collected upon presentation, followed by multivariate statistical analysis. RESULTS: Ninety-four PICU sepsis, 81 ED sepsis, and 63 ED control patients were included. Metabolomic profiling revealed clear separation of groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.89, area under the receiver operating characteristic curve (AUROC) of 0.96 (standard deviation [SD] 0.01), and predictive ability (Q(2)) of 0.60. Protein mediator profiling also showed clear separation of the groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.78 and AUROC of 0.88 (SD 0.03). Combining metabolomic and protein mediator profiling improved the model (Q(2) =0.62), differentiating PICU sepsis from ED sepsis with accuracy of 0.87 and AUROC of 0.95 (SD 0.01). Separation of PICU sepsis or ED sepsis from ED controls was even more accurate. Prespecified age subgroups (2–5 years old and 6–17 years old) improved model accuracy minimally. Seventeen metabolites or protein mediators accounted for separation of PICU sepsis and ED sepsis with 95 % confidence. CONCLUSIONS: In children ages 2–17 years, combining metabolomic and inflammatory protein mediator profiling early after presentation may differentiate children with sepsis requiring care in a PICU from children with or without sepsis safely cared for outside a PICU. This may aid in making triage decisions, particularly in an ED without pediatric expertise. This finding requires validation in an independent cohort. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1026-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4563828
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45638282015-09-10 Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis Mickiewicz, Beata Thompson, Graham C. Blackwood, Jaime Jenne, Craig N. Winston, Brent W. Vogel, Hans J. Joffe, Ari R. Crit Care Research INTRODUCTION: The first steps in goal-directed therapy for sepsis are early diagnosis followed by appropriate triage. These steps are usually left to the physician’s judgment, as there is no accepted biomarker available. We aimed to determine biomarker phenotypes that differentiate children with sepsis who require intensive care from those who do not. METHODS: We conducted a prospective, observational nested cohort study at two pediatric intensive care units (PICUs) and one pediatric emergency department (ED). Children ages 2–17 years presenting to the PICU or ED with sepsis or presenting for procedural sedation to the ED were enrolled. We used the judgment of regional pediatric ED and PICU attending physicians as the standard to determine triage location (PICU or ED). We performed metabolic and inflammatory protein mediator profiling with serum and plasma samples, respectively, collected upon presentation, followed by multivariate statistical analysis. RESULTS: Ninety-four PICU sepsis, 81 ED sepsis, and 63 ED control patients were included. Metabolomic profiling revealed clear separation of groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.89, area under the receiver operating characteristic curve (AUROC) of 0.96 (standard deviation [SD] 0.01), and predictive ability (Q(2)) of 0.60. Protein mediator profiling also showed clear separation of the groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.78 and AUROC of 0.88 (SD 0.03). Combining metabolomic and protein mediator profiling improved the model (Q(2) =0.62), differentiating PICU sepsis from ED sepsis with accuracy of 0.87 and AUROC of 0.95 (SD 0.01). Separation of PICU sepsis or ED sepsis from ED controls was even more accurate. Prespecified age subgroups (2–5 years old and 6–17 years old) improved model accuracy minimally. Seventeen metabolites or protein mediators accounted for separation of PICU sepsis and ED sepsis with 95 % confidence. CONCLUSIONS: In children ages 2–17 years, combining metabolomic and inflammatory protein mediator profiling early after presentation may differentiate children with sepsis requiring care in a PICU from children with or without sepsis safely cared for outside a PICU. This may aid in making triage decisions, particularly in an ED without pediatric expertise. This finding requires validation in an independent cohort. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1026-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-09 2015 /pmc/articles/PMC4563828/ /pubmed/26349677 http://dx.doi.org/10.1186/s13054-015-1026-2 Text en © Mickiewicz et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mickiewicz, Beata
Thompson, Graham C.
Blackwood, Jaime
Jenne, Craig N.
Winston, Brent W.
Vogel, Hans J.
Joffe, Ari R.
Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title_full Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title_fullStr Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title_full_unstemmed Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title_short Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
title_sort development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563828/
https://www.ncbi.nlm.nih.gov/pubmed/26349677
http://dx.doi.org/10.1186/s13054-015-1026-2
work_keys_str_mv AT mickiewiczbeata developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT thompsongrahamc developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT blackwoodjaime developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT jennecraign developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT winstonbrentw developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT vogelhansj developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT joffearir developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis
AT developmentofmetabolicandinflammatorymediatorbiomarkerphenotypingforearlydiagnosisandtriageofpediatricsepsis